Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4007129 | 0.89 | L3MBTL1 (0.53) | MEN1KMT2ACYP2C9MAPK14SMN1; SMN2 | |
| SCHEMBL4006524 | 0.89 | MAPK14 (0.49) | MEN1KMT2ACYP2C9MAPK14SMN1; SMN2 | |
| SCHEMBL3409240 | 0.86 | L3MBTL1 (0.57) | MEN1KMT2ACYP2C9MAPK14SMN1; SMN2 | |
| SCHEMBL4007875 | 0.83 | MAPK14 (0.50) | MEN1KMT2ACYP2C9MAPK14SMN1; SMN2 | |
| SCHEMBL4005974 | 0.83 | NPC1 (0.71) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL3404706 | 0.81 | HDAC6 (0.55) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL4648730 | 0.81 | HDAC6 (0.58) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL4007507 | 0.80 | NPC1 (0.54) | KMT2ACYP2C9MAPK14NPC1HPGD | |
| SCHEMBL3412142 | 0.80 | HDAC6 (0.60) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL4008158 | 0.78 | L3MBTL1 (0.54) | SMN1; SMN2NPC1RAB9AGABRA5L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | claimed |
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| WO-2009082346-A1 | NEW ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS AND USES IN TREATMENTS OF OBESITY AND DIABETES MELLITUS - 087 | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ACACA, ACACB, ACAT1 | MEN1 4443/4885KMT2A 1754/4885CYP2C9 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.